Eli Lilly (NYSE: LLY) reports 21.99M-share beneficial stake in ProQR Therapeutics

Rhea-AI Filing Summary

Eli Lilly and Company reports beneficial ownership of 21,995,880 ordinary shares of ProQR Therapeutics N.V., representing 15.6% of the outstanding class of ordinary shares with a nominal value of 0.04 EUR per share.

Eli Lilly holds sole voting power and sole dispositive power over all 21,995,880 shares and reports no shared voting or dispositive power. The filing is signed by Christopher Anderson, Vice President - Leader of Corporate Securities and Assistant Corporate Secretary.

Key Figures

Beneficial ownership: 21,995,880 shares Ownership percentage: 15.6% Sole voting power: 21,995,880 shares +2 more

5 metrics

Beneficial ownership 21,995,880 shares Ordinary shares of ProQR Therapeutics N.V. beneficially owned by Eli Lilly and Company

Ownership percentage 15.6% Percent of ProQR’s outstanding ordinary share class held by Eli Lilly

Sole voting power 21,995,880 shares Shares for which Eli Lilly has sole power to vote or direct the vote

Sole dispositive power 21,995,880 shares Shares for which Eli Lilly has sole power to dispose or direct disposition

Nominal value per share 0.04 EUR per share Nominal value of ProQR ordinary shares held by Eli Lilly

Key Terms

beneficially owned, sole voting power, sole dispositive power, ordinary shares, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 21,995,880"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 21,995,880"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 21,995,880"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

ordinary shares financial

"Title of class of securities: Ordinary Shares, nominal value 0.04 EUR per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Schedule 13G regulatory

"Amendment No. 2 to Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 04:31 PM Accepted by SEC EDGAR 07/24/2026 - 04:30 PM Learn about SEC filing dates

FAQ

How many ProQR Therapeutics (PRQR) shares does Eli Lilly beneficially own?

Eli Lilly and Company beneficially owns 21,995,880 ordinary shares of ProQR Therapeutics N.V. These shares represent a significant stake in ProQR’s ordinary share capital as disclosed in the Schedule 13G/A filing.

What percentage of ProQR Therapeutics (PRQR) does Eli Lilly hold?

Eli Lilly and Company holds 15.6% of ProQR Therapeutics N.V.’s outstanding ordinary shares. This percentage is explicitly identified as Eli Lilly’s beneficial ownership of the class in the Schedule 13G/A amendment.

Does Eli Lilly have sole or shared voting power over its PRQR shares?

Eli Lilly has sole voting power over 21,995,880 ProQR shares and no shared voting power. The same 21,995,880 shares are also subject to Eli Lilly’s sole dispositive power, with no shared dispositive power reported.

What class of ProQR Therapeutics (PRQR) securities is held by Eli Lilly?

Eli Lilly holds ProQR’s ordinary shares, each with a nominal value of 0.04 EUR per share. The holding relates specifically to this class of securities, identified by CUSIP number N71542109 in the ownership disclosure.

Who signed the ownership report relating to ProQR Therapeutics (PRQR) for Eli Lilly?

The report is signed by Christopher Anderson, identified as Vice President - Leader of Corporate Securities and Assistant Corporate Secretary. The signature date is 07/24/2026, confirming the information on behalf of Eli Lilly and Company.

What type of filing did Eli Lilly submit regarding its stake in ProQR (PRQR)?

Eli Lilly submitted an Amendment No. 2 to Schedule 13G regarding its ProQR holdings. This type of filing reports beneficial ownership of a company’s equity securities by large holders such as institutional investors or corporations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ProQR Therapeutics N.V.

(Name of Issuer)

Ordinary Shares, nominal value 0.04 EUR per share

(Title of Class of Securities)

N71542109

(CUSIP Number)

06/26/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): N71542109

1

Names of Reporting Persons

ELI LILLY & Co

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

INDIANA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 21,995,880.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 21,995,880.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

21,995,880.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.6 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ProQR Therapeutics N.V.
(b)	Address of issuer's principal executive offices: ZERNIKEDREEF 9, LEIDEN, NETHERLANDS, 2333 CK
Item 2.
(a)	Name of person filing: Eli Lilly and Company
(b)	Address or principal business office or, if none, residence: Lilly Corporate Center Indianapolis, Indiana 46285
(c)	Citizenship: Eli Lilly and Company is an Indiana corporation
(d)	Title of class of securities: Ordinary Shares, nominal value 0.04 EUR per share
(e)	CUSIP No.: N71542109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 21,995,880
(b)	Percent of class: 15.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 21,995,880
	(ii) Shared power to vote or to direct the vote: N/A
	(iii) Sole power to dispose or to direct the disposition of: 21,995,880
	(iv) Shared power to dispose or to direct the disposition of: N/A
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ELI LILLY & Co

Signature:	/s/ Christopher Anderson
Name/Title:	Vice President - Leader of Corporate Securities and Assistant Corporate Secretary
Date:	07/24/2026